BRD2 and cancer: It was not considered a TSA in S1 originally owing to the level of expression in normal tissue (RNA coding sequences not expressed at least 10-fold higher in cancer than in NAT), and yet at the immunopeptidomic level it had a 3.5-fold higher intensity in CRC than in NAT.